Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 1101–1120 of 1,190 studiesSort:

CompletedInterventional · Not applicableNCT05385952 ↗
A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of GATT-Patch Versus TachoSil for Hemostasis During Open Liver Surgery
Benjamin SamsteinPI
Intervention
Device: GATT-Patch (currently named ETHIZIA) · Drug: TachoSil
Dates
Aug 2022 – May 2024

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 1101–1120 of 1,190 studiesSort:

CompletedInterventional · Not applicableNCT05385952 ↗
A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of GATT-Patch Versus TachoSil for Hemostasis During Open Liver Surgery
Benjamin SamsteinPI
Intervention
Device: GATT-Patch (currently named ETHIZIA) · Drug: TachoSil
Dates
Aug 2022 – May 2024

Phase 2/3

Early phase 13

Harini Sarva21
Ashish Saxena20
Cora Sternberg20
Ellen K. Ritchie18
Ruben Niesvizky16
Dana Jeremy Lukin14
Evelyn M. Horn14
Pinkal Desai14
Ellen J Scherl13
Daniel W Skupski12
Eleni Andreopoulou12
Jim W. Cheung12
Jia Ruan12
Massimo Cristofanilli12
Sujit Sheth12
Catherine Butkus Small11
James E. Ip11
John Allan11
Anna C Pavlick10
Alexander Ja-Ho Chou10
Aliza B Solomon10
Alpana P. Shukla10
Marshall J. Glesby10
Anna Podolanczuk9
Barbara Ma9
Catherine McGuinn9
Silvia Chiara Formenti9
Hani Lamie Ashamalla9
Kristen Marks9
Robert J. Kaner9
Shari Lipner9
Maria Teresa DeSancho8
Samuel Kim8
Andrew F. Alexis7
Erin Mulvey7
Evelyn Cantillo7
Jean W. Pape7
Sebastian A. Mayer7
Brian DeRubertis6
Conor Liston6
Darshana M Dadhania6
David M Nanus6
Joseph M Scandura6
Lok W. Yung6
Mehraneh Dorna Jafari6

Neurological Surgery19

Cardiothoracic Surgery17

Urology15

Rehabilitation Medicine13

Population Health Sciences9

Otolaryngology Head and Neck Surgery7

Pathology and Laboratory Medicine1

Pharmacology1

Show fewer

Carcinoma, Non-Small-Cell Lung27
Multiple Myeloma27
Colitis, Ulcerative26
Crohn Disease26
Myelodysplastic Syndromes26
Recurrence25
Atrial Fibrillation23
Neoplasm Metastasis23
Obesity23
Parkinson Disease21
COVID-1920
Colorectal Neoplasms18
Depression18
Cardiovascular Diseases17
Hematologic Neoplasms17
HIV Infections16
Non-alcoholic Fatty Liver Disease15
Overweight15
Melanoma13
Idiopathic Pulmonary Fibrosis12
Inflammatory Bowel Diseases12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lung Neoplasms12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Hypertension11
Myeloproliferative Disorders11
Alzheimer Disease10
Coronary Artery Disease10
Hypertension, Pulmonary10
Leukemia, Myelomonocytic, Chronic10
Stroke10
Urinary Bladder Neoplasms10
Cognitive Dysfunction9
Leukemia9
Lung Diseases, Interstitial9
Pulmonary Arterial Hypertension9
Burkitt Lymphoma8
Carcinoma, Renal Cell8
Chronic Pain8
Fibrosis8
Lymphoma, Follicular8
Lymphoma, Large B-Cell, Diffuse8
Adenocarcinoma Of Esophagus7
Anemia7

Radiation

Diagnostic test22

Dietary supplement14

Combination product11

Genetic6

· Results posted

Sponsor

GATT Technologies B.V.

Intraoperative BleedingHemorrhage, SurgicalLiver Diseases

CompletedInterventional · Phase 3NCT05394519 ↗

Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes

Alpana P. ShuklaPI

Intervention: Drug: Cagrilintide · Drug: Semaglutide · Drug: Placebo cagrilintide · Drug: Placebo semaglutide
Dates: Feb 2023 – Jan 2025
Sponsor: Novo Nordisk Pharmaceuticals, Inc.

OverweightObesityType 2 Diabetes Mellitus

CompletedInterventional · Not applicableNCT05396443 ↗

A Telehealth Lifestyle Intervention for Black Adolescent Girls at Risk for Type 2 Diabetes: A Pilot Study

Tashara Marie LeakPI

Intervention: Behavioral: Black Girls for Wellness Telehealth
Dates: Aug 2022 – Feb 2025
Sponsor: Weill Medical College of Cornell University

Obesity, ChildhoodType2Diabetes

CompletedInterventional · Phase 1/2NCT05399654 ↗

A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Anna C PavlickPI

Intervention: Drug: TAC-001
Dates: Jun 2022 – Jan 2026 (est.)
Sponsor: Tallac Therapeutics, Inc.

Advanced or Metastatic Solid Tumors

TerminatedInterventional · Phase 2NCT05403476 ↗

A Randomised, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of FE 999049 for Treatment of Men With Idiopathic Infertility

James A. KashanianPI

Intervention: Drug: FE 999049 · Drug: Placebo
Dates: Aug 2022 – Oct 2024· Results posted
Sponsor: Ferring Pharmaceuticals, Inc.

Male Idiopathic Infertility

TerminatedInterventional · Phase 3NCT05418673 ↗

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants With Parkinson's Disease and Pathogenic LRRK2 Variants

Harini SarvaPI

Intervention: Drug: BIIB122 · Drug: BIIB122-Matching Placebo
Dates: Aug 2022 – Jul 2023· Results posted
Sponsor: Biogen, Inc.

Parkinson Disease

TerminatedInterventional · Phase 1/2NCT05427812 ↗

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma

Ruben NiesvizkyPI

Intervention: Drug: ISB 1442 SC injection escalating doses · Drug: ISB 1442 SC injection at RP2D
Dates: Sep 2022 – Nov 2024
Sponsor: Ichnos Sciences S.A.

Relapsed/Refractory Multiple Myeloma

CompletedInterventional · Not applicableNCT05443594 ↗

A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation

Jim W. CheungPI

Intervention: Device: Phase 1: FARAPULSE Ablation System · Device: Phase 2: FARAPULSE Ablation System
Dates: Feb 2023 – Feb 2025· Results posted
Sponsor: Boston Scientific Corporation

Persistent Atrial Fibrillation

CompletedInterventional · Phase 2NCT05480306 ↗

Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)

Despina SiolasPI

Intervention: Drug: DKN-01 · Drug: FOLFIRI · Drug: Bevacizumab · Drug: FOLFOX
Dates: Aug 2022 – Jul 2025
Sponsor: Leap Therapeutics, Inc.

Colorectal CancerColorectal AdenocarcinomaColo-rectal Cancer+1 more

TerminatedInterventional · Phase 1NCT05511844 ↗

Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Massimo CristofanilliPI

Intervention: Drug: ORM-5029
Dates: Oct 2022 – Jun 2025
Sponsor: Orum Therapeutics, Inc.

HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene Amplification+1 more

TerminatedInterventional · Phase 3NCT05534984 ↗

A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Virus Disease

Marshall J. GlesbyPI

Intervention: Drug: Tecovirimat Oral Capsule · Drug: Placebo for Tecovirimat · Drug: Tecovirimat Oral Capsule (Open Label)
Dates: Sep 2022 – Oct 2024· Results posted
Sponsor: National Institute of Allergy & Infectious Diseases

MPOX

CompletedInterventional · Phase 4NCT05544734 ↗

Analysis of Hydrocodone Compared to Acetaminophen and Ibuprofen for Post-nail Procedure Analgesia

Shari LipnerPI

Intervention: Drug: Hydrocodone 5Mg/Acetaminophen 325Mg Tab · Drug: Acetaminophen 1000mg · Drug: Ibuprofen 400 mg
Dates: Nov 2022 – May 2023· Results posted
Sponsor: Weill Medical College of Cornell University

Nail DiseasesNail Abnormality

CompletedInterventional · Phase 2NCT05551273 ↗

Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

Kristen MarksPI

Intervention: Drug: Selgantolimod · Drug: Placebo
Dates: May 2023 – Oct 2025
Sponsor: National Institute of Allergy & Infectious Diseases

Hepatitis BHIV Infections

TerminatedInterventional · Phase 1NCT05556616 ↗

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma

Ruben NiesvizkyPI

Intervention: Drug: Modakafusp alfa · Drug: Lenalidomide · Drug: Bortezomib · Drug: Carfilzomib · Drug: Daratumumab · Drug: Pomalidomide
Dates: Jan 2023 – Jun 2024· Results posted
Sponsor: Takeda Development Center Americas, Inc.

Multiple Myeloma

CompletedInterventional · Not applicableNCT05565534 ↗

Optimizing Delivery of Diabetes Management During Breast Cancer Care

Laura PinheiroPI

Intervention: Behavioral: Nurse-practitioner led intervention
Dates: Feb 2023 – Jul 2025· Results posted
Sponsor: Weill Medical College of Cornell University

Breast CancerPreDiabetesType 2 Diabetes

CompletedInterventional · Phase 2NCT05571293 ↗

Novel Exploratory Study to Test Combination of Botensilimab and Balstilimab Immunotherapy in Resectable Colorectal Cancer Patients

Manish A ShahPI

Intervention: Drug: Botensilimab · Drug: Balstilimab
Dates: Mar 2023 – Nov 2024· Results posted
Sponsor: Weill Medical College of Cornell University

Colorectal Neoplasms

TerminatedInterventional · Phase 4NCT05582681 ↗

HCV Test and Treat Utilizing Simplified HCV Patient Education

Robert S. BrownPI

Intervention: Diagnostic test: Cepheid POC HCV Viremia (RNA) test · Other: HCV education from a health care provider · Drug: Glecaprevir and Pibrentasvir
Dates: Nov 2022 – Nov 2024
Sponsor: Weill Medical College of Cornell University

Hepatitis C

CompletedInterventional · Phase 3NCT05587309 ↗

A Phase 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

Felice H Schnoll-SussmanPI

Intervention: Drug: BLI5100 · Drug: PPI Control
Dates: Oct 2022 – Jun 2025
Sponsor: Braintree Laboratories, INC

Erosive Esophagitis

CompletedInterventional · Phase 3NCT05587322 ↗

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

Felice H Schnoll-SussmanPI

Intervention: Drug: BLI5100 · Drug: Placebo
Dates: Sep 2022 – Oct 2023
Sponsor: Braintree Laboratories, INC

Non-erosive Reflux Disease

CompletedInterventional · Phase 2NCT05595369 ↗

RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Matthew William McCarthyPI

Intervention: Drug: Experimental: Paxlovid 25 day dosing · Drug: Experimental: Paxlovid 15 day dosing · Drug: Placebo Comparator: Control
Dates: Jul 2023 – Aug 2024· Results posted
Sponsor: Duke University

Long COVIDLong Covid19

‹ Prev 1 2 3 4 5…55 56 57 58 59 60 Next ›